• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fluvoxamine, melatonin and COVID-19.

作者信息

Anderson George M

机构信息

Child Study Center and the Department of Laboratory Medicine, Yale University School of Medicine, 230 S. Frontage Rd., New Haven, CT, 06525, USA.

出版信息

Psychopharmacology (Berl). 2021 Feb;238(2):611. doi: 10.1007/s00213-020-05753-z. Epub 2021 Jan 4.

DOI:10.1007/s00213-020-05753-z
PMID:33392622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7779245/
Abstract
摘要

相似文献

1
Fluvoxamine, melatonin and COVID-19.氟伏沙明、褪黑素与新型冠状病毒肺炎
Psychopharmacology (Berl). 2021 Feb;238(2):611. doi: 10.1007/s00213-020-05753-z. Epub 2021 Jan 4.
2
COVID-19 Infection-Preventing Clinical Deterioration.预防新型冠状病毒肺炎感染导致的临床病情恶化
JAMA. 2020 Dec 8;324(22):2300. doi: 10.1001/jama.2020.21720.
3
Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?服用抗抑郁药和/或抗精神病药的人是否可能对重症 COVID-19 有更好的防护作用？
Pharmacopsychiatry. 2021 May;54(3):142-143. doi: 10.1055/a-1408-8298. Epub 2021 Mar 17.
4
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.一项系统评价和荟萃分析，研究了氟伏沙明治疗 COVID-19 病情恶化、死亡和长期 COVID 并发症的剂量和时间疗效。
Sci Rep. 2024 Jun 12;14(1):13462. doi: 10.1038/s41598-024-64260-9.
5
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.氟伏沙明治疗 SARS-CoV-2 感染的早期治疗：当前证据综述。
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
6
The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial).氟伏沙明治疗轻症至中症 COVID-19 患者的真实世界疗效：一项历史性队列研究（氟伏沙明试验）。
J Infect Public Health. 2023 Dec;16(12):2010-2016. doi: 10.1016/j.jiph.2023.10.010. Epub 2023 Oct 6.
7
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.氟伏沙明对比安慰剂在伴有症状的 COVID-19 门诊患者中的临床恶化：一项随机临床试验。
JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.
8
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.高剂量氟伏沙明与 COVID-19 门诊患者持续康复时间：ACTIV-6 随机临床试验。
JAMA. 2023 Dec 26;330(24):2354-2363. doi: 10.1001/jama.2023.23363.
9
Fluvoxamine for the treatment of COVID-19.氟伏沙明治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Sep 14;9(9):CD015391. doi: 10.1002/14651858.CD015391.
10
Heme oxygenase agonists-fluvoxamine, melatonin-are efficacious therapy for Covid-19.血红素加氧酶激动剂——氟伏沙明、褪黑素——是治疗新冠肺炎的有效疗法。
Cell Stress Chaperones. 2022 Jan;27(1):3-4. doi: 10.1007/s12192-021-01246-w. Epub 2021 Nov 30.

引用本文的文献

1
Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches.长新冠的神经精神表现：临床方面与治疗方法的叙述性综述
Life (Basel). 2025 Mar 11;15(3):439. doi: 10.3390/life15030439.
2
Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: a retrospective cohort study using real-world data.抗抑郁药与新型冠状病毒奥密克戎变异株感染严重程度之间的关系：一项使用真实世界数据的回顾性队列研究
Lancet Reg Health West Pac. 2023 May;34:100716. doi: 10.1016/j.lanwpc.2023.100716. Epub 2023 Feb 27.
3
The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis.选择性5-羟色胺和去甲肾上腺素再摄取抑制剂对新型冠状病毒肺炎患者临床结局的影响：一项系统评价和荟萃分析
Health Sci Rep. 2022 Oct 17;5(6):e892. doi: 10.1002/hsr2.892. eCollection 2022 Nov.
4
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment.新冠后抑郁症状：流行病学、病理生理学和药物治疗。
CNS Drugs. 2022 Jul;36(7):681-702. doi: 10.1007/s40263-022-00931-3. Epub 2022 Jun 21.
5
Mechanisms of action of fluvoxamine for COVID-19: a historical review.氟伏沙明治疗 COVID-19 的作用机制：历史回顾。
Mol Psychiatry. 2022 Apr;27(4):1898-1907. doi: 10.1038/s41380-021-01432-3. Epub 2022 Jan 7.
6
Sleep Dysfunction in COVID-19 Patients: Prevalence, Risk Factors, Mechanisms, and Management.新冠病毒感染患者的睡眠功能障碍：患病率、危险因素、机制及管理
J Pers Med. 2021 Nov 14;11(11):1203. doi: 10.3390/jpm11111203.
7
Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder.调节 COVID-19 合并强迫症患者的神经炎症。
J Psychiatr Res. 2022 May;149:367-373. doi: 10.1016/j.jpsychires.2021.11.025. Epub 2021 Nov 17.
8
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.氟伏沙明治疗 COVID-19 重症监护病房患者的安全性和有效性：一项开放标签、前瞻性队列研究，设有匹配对照。
Br J Clin Pharmacol. 2022 May;88(5):2065-2073. doi: 10.1111/bcp.15126. Epub 2021 Dec 1.
9
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.氟伏沙明早期治疗对 COVID-19 患者急诊和住院风险的影响：TOGETHER 随机、平台临床试验。
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
10
Recent advances in management of COVID-19: A review.近期 COVID-19 管理进展：综述。
Biomed Pharmacother. 2021 Nov;143:112107. doi: 10.1016/j.biopha.2021.112107. Epub 2021 Aug 27.

本文引用的文献

1
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.氟伏沙明对比安慰剂在伴有症状的 COVID-19 门诊患者中的临床恶化：一项随机临床试验。
JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.